{
  "schemaVersion": 2,
  "eyebrow": "Allergy and Immunology",
  "title": "Anaphylaxis",
  "summary": "Recognize anaphylaxis clinically, administer intramuscular epinephrine without delay, support airway and circulation, and escalate promptly when symptoms persist. Observation, discharge preparedness, and allergy evaluation reduce risk from recurrence, biphasic reactions, and avoidable re-exposure.",
  "seoDescription": "Point-of-care diagnosis and emergency management of anaphylaxis, including epinephrine dosing, refractory reactions, observation, discharge planning, and follow-up.",
  "clinicalQuestion": "How should physicians diagnose, treat, monitor, and prevent recurrence after suspected anaphylaxis?",
  "specialty": "Allergy and Immunology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "anaphylaxis",
    "epinephrine",
    "intramuscular epinephrine",
    "biphasic anaphylaxis",
    "refractory anaphylaxis",
    "serum tryptase",
    "epinephrine autoinjector"
  ],
  "keyTakeaways": [
    "Diagnose clinically; do not defer epinephrine for laboratory confirmation or because cutaneous findings are absent. [12][18]",
    "For anaphylaxis, administer epinephrine 1 mg/mL intramuscularly into the anterolateral thigh: adults and patients weighing 30 kg or more, 0.3-0.5 mg; patients under 30 kg, 0.01 mg/kg, maximum 0.3 mg. Repeat every 5-10 minutes as needed. [1][3]",
    "Antihistamines, corticosteroids, and inhaled beta2-agonists are adjuncts; none substitutes for epinephrine in airway, respiratory, or circulatory involvement. [18][22]",
    "Persistent anaphylaxis after 2-3 appropriate IM doses plus resuscitation should trigger critical-care escalation, IV epinephrine infusion by experienced staff, and aggressive fluid therapy with continuous monitoring. [20]",
    "At discharge, address trigger avoidance, prescribe and teach epinephrine autoinjector use, and arrange allergy evaluation; early specialist assessment is important when the trigger is uncertain or drug-related. [19][21]"
  ],
  "sections": [
    {
      "id": "clinical-recognition",
      "eyebrow": "Diagnosis",
      "heading": "Recognize anaphylaxis clinically",
      "intro": "The immediate decision is whether airway, breathing, or circulation involvement warrants epinephrine.",
      "paragraphs": [
        "Anaphylaxis is highly likely with acute skin or mucosal involvement plus respiratory compromise or hypotension/end-organ symptoms; with rapid involvement of at least two systems after a likely allergen; or with hypotension after a known allergen. For adults, hypotension is systolic blood pressure below 90 mm Hg or a decrease greater than 30% from baseline. [18]",
        "Absence of hives or angioedema does not exclude anaphylaxis. This is particularly important in perioperative reactions, where cardiovascular and respiratory compromise may predominate, and in patients with abrupt bronchospasm, laryngeal symptoms, or hypotension after a probable exposure. [12][22]",
        "Treat the clinical syndrome rather than waiting for confirmatory testing. Serum tryptase may support retrospective confirmation, but it lacks sensitivity and should not alter immediate resuscitation. Paired acute and baseline samples are more informative than a single value; one review describes acute sampling between 30 minutes and 2 hours after symptom onset and baseline sampling at least 24 hours after complete resolution. [22]"
      ],
      "bullets": [
        "Ask specifically about timing and route of exposure; foods, medications, insect venom, latex, diagnostic agents, and exercise-associated reactions are common contexts. [1][10][12]",
        "Document objective airway, respiratory, circulatory, gastrointestinal, and skin findings; this supports later trigger assessment and risk stratification. [18][19]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical features that should prompt treatment for anaphylaxis rather than isolated allergic symptoms. [18]",
        "columns": [
          "Presentation",
          "Action"
        ],
        "rows": [
          [
            "Acute skin or mucosal symptoms plus dyspnea, wheeze, stridor, hypoxemia, or hypotension",
            "Treat as anaphylaxis with IM epinephrine. [18]"
          ],
          [
            "Rapid multisystem reaction after likely allergen, including persistent vomiting or abdominal cramping with skin, respiratory, or circulatory findings",
            "Treat as anaphylaxis with IM epinephrine. [18]"
          ],
          [
            "Acute bronchospasm, laryngeal involvement, or hypotension after known or probable allergen, with or without rash",
            "Treat as anaphylaxis with IM epinephrine. [12][18]"
          ]
        ]
      }
    },
    {
      "id": "immediate-treatment",
      "eyebrow": "Emergency management",
      "heading": "Give intramuscular epinephrine first",
      "intro": "IM epinephrine is first-line therapy for airway, respiratory, or circulatory anaphylaxis.",
      "paragraphs": [
        "Use epinephrine 1 mg/mL IM in the anterolateral thigh. FDA labeling supports 0.3-0.5 mg for adults and children weighing 30 kg or more, and 0.01 mg/kg for children under 30 kg, with a maximum 0.3 mg per injection; repeat every 5-10 minutes as clinically necessary. The thigh is preferred because of its size and blood flow. [1][3]",
        "There are no absolute contraindications to epinephrine for life-threatening anaphylaxis. Cardiovascular disease, advanced age, hypertension, and beta-blocker treatment warrant monitoring but should not delay IM treatment. IV bolus epinephrine has substantially greater risk of overdose and cardiovascular complications than IM administration and should not be routine initial therapy outside monitored expert settings. [1][18][20]",
        "Position patients supine when circulatory compromise is present; patients with prominent respiratory distress may require a more upright position. Continuously reassess mental status, airway, respiratory effort, oxygenation, blood pressure, and perfusion. [18][20]"
      ],
      "bullets": [
        "Remove the suspected exposure when feasible, such as an insect stinger or ongoing medication/infusion, without delaying epinephrine. [18]",
        "Provide high-flow oxygen for respiratory or cardiovascular involvement and establish IV access. [18][22]",
        "Give isotonic crystalloid for hypotension or poor perfusion; guideline-based recommendations commonly begin with 20 mL/kg and titrate to response. [18]",
        "Prepare early for a difficult airway when progressive oropharyngeal edema, stridor, severe bronchospasm, or respiratory failure is present. [18]"
      ],
      "subsections": [
        {
          "heading": "Avoid administration errors",
          "paragraphs": [
            "For anaphylaxis, inject into the anterolateral thigh—not buttock, digits, hands, feet, or deltoid. Do not repeatedly use the same injection site. Undiluted epinephrine administered intravenously can cause abrupt severe hypertension and cerebral hemorrhage. [1][3]"
          ],
          "bullets": [
            "Inspect injectable epinephrine for discoloration or particulate matter before use when this does not delay emergency treatment. [1][3]",
            "Monitor for tachyarrhythmia, myocardial ischemia, hypertension, pulmonary edema, and transient hyperglycemia, especially with parenteral or IV treatment. [1][3]"
          ]
        }
      ],
      "table": {
        "caption": "Medication roles in acute anaphylaxis. [1][18][20]",
        "columns": [
          "Intervention",
          "Role and limitations"
        ],
        "rows": [
          [
            "Epinephrine IM",
            "First-line treatment for anaphylaxis; repeat every 5-10 minutes as needed. [1][3]"
          ],
          [
            "Inhaled beta2-agonist",
            "Adjunct for persistent bronchospasm or wheeze; does not treat upper-airway edema or shock. [18]"
          ],
          [
            "H1 antihistamine",
            "Adjunct for skin and mucosal symptoms after epinephrine; evidence for preventing biphasic reactions is uncertain. [18]"
          ],
          [
            "Systemic corticosteroid",
            "Not a substitute for epinephrine; evidence that it prevents biphasic anaphylaxis is uncertain and current literature questions routine use for that purpose. [7][18]"
          ],
          [
            "IV epinephrine infusion",
            "For persistent/refractory anaphylaxis in a monitored setting with clinicians experienced in titration and adverse-effect surveillance. [20]"
          ]
        ]
      }
    },
    {
      "id": "refractory-anaphylaxis",
      "eyebrow": "Escalation",
      "heading": "Escalate persistent or refractory anaphylaxis",
      "intro": "Persistent airway, respiratory, or circulatory manifestations require resuscitation-level care.",
      "paragraphs": [
        "Definitions vary, but contemporary guidance commonly treats failure to respond adequately after 2 doses of IM epinephrine as a trigger for escalation; a U.S. expert consensus definition uses three or more appropriate epinephrine doses or initiation of IV infusion in addition to symptom-directed management. [20]",
        "Reassess for continued allergen exposure, inadequate IM delivery, airway obstruction, profound distributive shock, and competing diagnoses. Give additional IM epinephrine while mobilizing critical-care support, providing airway management, and administering rapid IV crystalloid. [20]",
        "For persistent cardiovascular compromise despite appropriate IM epinephrine and fluids, most reviewed guidelines recommend titrated IV epinephrine infusion with close cardiopulmonary monitoring. The optimum infusion regimen and preferred add-on vasopressor remain uncertain because high-quality comparative data are lacking. [20]"
      ],
      "bullets": [
        "Use continuous ECG, oxygen saturation, frequent or invasive blood pressure monitoring, and close assessment of urine output and perfusion during IV epinephrine therapy. [1][20]",
        "For patients taking beta-blockers with epinephrine-resistant shock, glucagon is recommended in multiple guidelines, but supporting evidence is limited largely to case reports; monitor for vomiting, hyperglycemia, hypokalemia, and hypocalcemia. [20]",
        "Consider additional vasopressors such as norepinephrine or vasopressin only as expert-level adjuncts to, not replacements for, epinephrine infusion and volume resuscitation. [20]"
      ],
      "subsections": [],
      "table": {
        "caption": "Refractory-anaphylaxis priorities. [20]",
        "columns": [
          "Problem",
          "Immediate response"
        ],
        "rows": [
          [
            "Persistent hypotension or poor perfusion after repeated IM epinephrine",
            "Critical-care escalation, rapid crystalloid resuscitation, and titrated IV epinephrine infusion with continuous monitoring. [20]"
          ],
          [
            "Progressive laryngeal edema, severe stridor, or respiratory failure",
            "Early expert airway management; do not delay until complete obstruction. [18][20]"
          ],
          [
            "Ongoing shock despite epinephrine infusion and fluids",
            "Evaluate cardiac function and preload; consider additional vasopressor support under critical-care supervision. [20]"
          ],
          [
            "Beta-blocker exposure with epinephrine-resistant shock",
            "Consider glucagon as an adjunct; evidence is limited. [20]"
          ]
        ]
      }
    },
    {
      "id": "observation-and-disposition",
      "eyebrow": "Monitoring",
      "heading": "Individualize observation and disposition",
      "intro": "Biphasic recurrence is uncommon but clinically consequential and risk is not uniform.",
      "paragraphs": [
        "Biphasic anaphylaxis is recurrence after apparent resolution without re-exposure. Reported incidence varies substantially because of differing definitions; a recent case-based review cites 0.4% to 23.3%, with many datasets suggesting approximately 4%-6%. [7]",
        "Observation duration should reflect initial severity, response to treatment, need for repeated epinephrine, hypotension, persistent symptoms, asthma or other respiratory disease, access to emergency care, and ability to recognize and treat recurrence. Severe, protracted, multiphasic, or refractory reactions require extended monitored care or admission. [7][18][20]",
        "The evidence base does not yield a single universally validated observation interval. A guideline reviewed in the supplied literature recommends at least 12 hours of hospital monitoring after symptom relief, particularly for patients with hypotension, whereas other sources describe shorter risk-stratified observation for uncomplicated cases. [18][20]"
      ],
      "bullets": [
        "Before discharge, ensure sustained symptom resolution, stable vital signs, access to epinephrine, ability to use the device, a written emergency plan, and clear return precautions. [18][19]",
        "Admit or observe longer for airway intervention, refractory symptoms, hemodynamic instability, recurrent symptoms, or need for repeated epinephrine. [20][24]"
      ],
      "subsections": [],
      "table": {
        "caption": "Features associated with increased concern for recurrent or severe disease. [18][20]",
        "columns": [
          "Feature",
          "Disposition implication"
        ],
        "rows": [
          [
            "Hypotension, severe initial reaction, or repeated epinephrine doses",
            "Favor prolonged monitored observation or admission. [18][20]"
          ],
          [
            "Persistent or progressive symptoms",
            "Do not discharge; continue treatment and reassessment. [20]"
          ],
          [
            "History of biphasic reaction, beta-blocker use, limited emergency access, or inability to use an autoinjector",
            "Use a lower threshold for extended observation and comprehensive discharge planning. [24]"
          ],
          [
            "Uncomplicated response to one IM epinephrine dose with durable recovery",
            "Risk-stratified observation may be reasonable, but a universally optimal duration is not established. [18][20]"
          ]
        ]
      }
    },
    {
      "id": "post-event-evaluation",
      "eyebrow": "Secondary prevention",
      "heading": "Prevent recurrence after the acute event",
      "intro": "A complete discharge plan matters because recurrent exposure is often preventable.",
      "paragraphs": [
        "Refer patients after suspected anaphylaxis to an allergy service for trigger assessment, counseling, and prevention planning. Referral is especially important for an uncertain trigger, drug-associated reaction, venom reaction, perioperative event, or recurrent/idiopathic anaphylaxis. [19][21]",
        "Prescribe epinephrine autoinjector therapy and provide practical demonstration. Counseling should include recognition of respiratory and circulatory symptoms, immediate epinephrine use, emergency activation, avoidance of suspected triggers pending evaluation, and awareness that symptoms may recur after an initial response. [1][3][18]",
        "Review the medication list and document the suspected culprit with the clinical phenotype and timing, rather than applying an imprecise allergy label. For drug-induced anaphylaxis, report the event through appropriate pharmacovigilance systems and arrange formal allergy evaluation when future use may be clinically important. [18][19]"
      ],
      "bullets": [
        "Obtain acute and baseline tryptase when diagnostic clarification may influence future management, especially after severe, idiopathic, recurrent, or perioperative reactions. [7][22]",
        "Elevated baseline tryptase or unusually severe reactions may warrant evaluation for mast cell disorders or hereditary alpha-tryptasemia in appropriate clinical contexts. [20][22]",
        "For venom anaphylaxis, allergy assessment can identify candidates for venom immunotherapy. [22]"
      ],
      "subsections": [],
      "table": {
        "caption": "High-value discharge elements after anaphylaxis. [18][19][21]",
        "columns": [
          "Element",
          "Clinical purpose"
        ],
        "rows": [
          [
            "Epinephrine autoinjector prescription and hands-on teaching",
            "Enables immediate treatment of recurrence outside medical settings. [1][3][18]"
          ],
          [
            "Written emergency action plan and return precautions",
            "Reinforces when to use epinephrine and seek emergency care. [18][21]"
          ],
          [
            "Trigger documentation and avoidance guidance",
            "Reduces re-exposure while evaluation is pending. [18][19]"
          ],
          [
            "Allergy/immunology referral",
            "Supports identification of culprit, risk stratification, and preventive treatment. [19][21]"
          ],
          [
            "Medication adverse-event reporting when applicable",
            "Supports pharmacovigilance for suspected drug-induced anaphylaxis. [18]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "Should epinephrine be given when anaphylaxis is suspected but diagnostic criteria are not fully met?",
      "answer": "When acute exposure-associated symptoms suggest evolving airway, respiratory, or circulatory involvement, administer IM epinephrine rather than waiting for diagnostic certainty. Clinical criteria are aids to recognition, not prerequisites for treatment. [12][18]"
    },
    {
      "question": "When should serum tryptase be measured?",
      "answer": "Tryptase is not needed to initiate treatment. When diagnostic confirmation is useful, obtain an acute sample as soon as feasible after stabilization and a baseline sample at least 24 hours after complete clinical resolution; paired values are more informative than a single measurement. [7][22]"
    },
    {
      "question": "Do antihistamines or corticosteroids prevent biphasic anaphylaxis?",
      "answer": "Evidence is uncertain. H1 antihistamines may relieve skin and mucosal symptoms after epinephrine, but they do not replace epinephrine. Systemic corticosteroids have not shown clear benefit for preventing biphasic reactions in available reviews. [7][18][22]"
    },
    {
      "question": "What defines refractory anaphylaxis?",
      "answer": "Definitions differ. Failure to respond adequately after two IM epinephrine doses is commonly used to trigger escalation; U.S. expert consensus has defined refractory anaphylaxis as requiring three or more appropriate doses or initiation of IV epinephrine infusion with adjunctive management. [20]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "DailyMed - ADRENALIN- epinephrine injection",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 2,
      "title": "- IIER - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 3,
      "title": "These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION.\n      EPINEPHRINE injection, for intravenous, intramuscular, subcutaneous useInitial U.S. Approval: 1939",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4f83895f-638c-4515-af03-7c41ae60a42e",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 4,
      "title": "safely and effectively. See full prescribing information ...",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a1758142-a905-401d-8961-05829f51023a&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 5,
      "title": "highlights of prescribing information",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 6,
      "title": "Food and Drug Administration",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s025lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 7,
      "title": "Multiphasic anaphylaxis in the emergency and intensive care setting | BMJ Case Reports",
      "detail": "casereports.bmj.com",
      "url": "https://casereports.bmj.com/content/19/2/e270996",
      "authors": "casereports.bmj.com",
      "host": "casereports.bmj.com"
    },
    {
      "number": 8,
      "title": "Guidelines for the management of anaphylaxis in ...",
      "detail": "emj.bmj.com",
      "url": "https://emj.bmj.com/content/15/2/96",
      "authors": "emj.bmj.com",
      "host": "emj.bmj.com"
    },
    {
      "number": 9,
      "title": "G462(P) Anaphylaxis nice guidelines: are we following ...",
      "detail": "adc.bmj.com",
      "url": "https://adc.bmj.com/content/104/Suppl_2/A186.3",
      "authors": "adc.bmj.com",
      "host": "adc.bmj.com"
    },
    {
      "number": 10,
      "title": "Anaphylaxis - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/501",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 11,
      "title": "Anaphylaxis: a guide to management Online course",
      "detail": "new-learning.bmj.com",
      "url": "https://new-learning.bmj.com/course/5001088",
      "authors": "new-learning.bmj.com",
      "host": "new-learning.bmj.com"
    },
    {
      "number": 12,
      "title": "Anaphylaxis - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/501",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 13,
      "title": "Integrated phase I pharmacokinetics and ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1081120625000092",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 14,
      "title": "Review Innovations in the treatment of anaphylaxis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1081120623004040",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 15,
      "title": "Generic substitution of epinephrine autoinjectors",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2772829323000954",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 16,
      "title": "Pediatric drug-induced anaphylaxis reports in the FDA ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2213219824005737",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 17,
      "title": "NATIONAL INSTITUTE FOR HEALTH AND CLINICAL ...",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng258/evidence/anaphylaxis-full-guideline-appendix-c-and-d-pdf-184946942",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 18,
      "title": "A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020)",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8996305",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "Overview | Anaphylaxis: assessment and referral after emergency treatment | Guidance | NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng258",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 20,
      "title": "Management of Refractory Anaphylaxis: An Overview of Current Guidelines",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11439156",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Evaluating the management of anaphylaxis in US emergency departments: Guidelines vs. practice",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4129832",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Recent update on the management of anaphylaxis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8517462",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Anaphylaxis - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK551995",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "Anaphylaxis - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK482124",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "DailyMed - ADRENALIN- epinephrine injection",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b7a4364-668d-4eb2-a20c-04adc35aabe4",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "To report SUSPECTED ADVERSE REACTIONS, contact Par Health at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\n\n# DRUG INTERACTIONS\n\n# USE IN SPECIFIC POPULATIONS\n\nSee 17 for PATIENT COUNSELING INFORMATION.\n\nRevised: 6/2026\n\n# FULL PRESCRIBING INFORMATION: CONTENTS\\\n\n# 1 INDICATIONS A",
      "score": 0.34826875
    },
    {
      "number": 2,
      "title": "- IIER - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "\"\" Net Content Statement 1118IN. SSQ,KORl.£55 1 /111, MOll:TIWI 550. 11. IIIT NOT MOIETIM 25 SQ. IN. 111GIN. MOll:TIWI 25 SQ. IN, 11/T NOTMOIET!wt 1 00&1l.K 11411. MOll:TIWI 100 SQ. IN. BUT NOT MOIETIM«ll Sil. K 1/2 II. <MR 400 SQ. IN. Drug Facts Format lnformat1on Drug Facts: 7.00 pt I SUbh eadings",
      "score": 0.3333301
    },
    {
      "number": 3,
      "title": "These highlights do not include all the information needed to use EPINEPHRINE INJECTION safely and effectively. See full prescribing information for EPINEPHRINE INJECTION.\n      EPINEPHRINE injection, for intravenous, intramuscular, subcutaneous useInitial U.S. Approval: 1939",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4f83895f-638c-4515-af03-7c41ae60a42e",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "## 2.2 Recommended Dosage and Administration Instructions for Anaphylaxis\n\nThe recommended dosage of Epinephrine Injection is based on weight and is provided in Table 1. Administer undiluted Epinephrine Injection intramuscularly or subcutaneously in the anterolateral aspect of the thigh.\n\nTable 1 Re",
      "score": 0.3233806
    },
    {
      "number": 4,
      "title": "safely and effectively. See full prescribing information ...",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a1758142-a905-401d-8961-05829f51023a&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "Neffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes, and can",
      "score": 0.28139865
    },
    {
      "number": 5,
      "title": "highlights of prescribing information",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "|  |  |  |  |\n ---  --- |\n| \\  Single dose unless otherwise noted.  †  AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses. | | | |\n|  |  |  |  |\n ---  --- |\n| Coadministered Drug   (Dose Regimen)\\ | Dapagliflozin   (Dose Regimen)\\ | Effect on Coadminis",
      "score": 0.24848904
    },
    {
      "number": 6,
      "title": "Food and Drug Administration",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s025lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "they respond differently compared to geriatric patients. 8.6 Hepatic Impairment No dose adjustment is recommended in patients with mild (bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) > ULN or bilirubin > 1x to 1.5x ULN and any AST) hepatic impairment. A recommended dos",
      "score": 0.22774443
    },
    {
      "number": 7,
      "title": "Multiphasic anaphylaxis in the emergency and intensive care setting | BMJ Case Reports",
      "detail": "casereports.bmj.com",
      "url": "https://casereports.bmj.com/content/19/2/e270996",
      "authors": "casereports.bmj.com",
      "host": "casereports.bmj.com",
      "snippet": "Guideline recommendations concerning biphasic anaphylaxis primarily address clinical monitoring. Despite this, optimal observation duration remains debated. Traditional observation periods range from 4 to 6hours following symptom resolution.7 The Dutch Nederlands Huisartsen Genootschap (NHG)1 and th",
      "score": 0.7265231
    },
    {
      "number": 8,
      "title": "Guidelines for the management of anaphylaxis in ...",
      "detail": "emj.bmj.com",
      "url": "https://emj.bmj.com/content/15/2/96",
      "authors": "emj.bmj.com",
      "host": "emj.bmj.com",
      "snippet": "by M Gavalas · 1998 · Cited by 76 — An algorithm for the emergency treatment of anaphylaxis is presented. Continuous assessment, monitoring of response to treatment, and a low threshold for",
      "score": 0.6708892
    },
    {
      "number": 9,
      "title": "G462(P) Anaphylaxis nice guidelines: are we following ...",
      "detail": "adc.bmj.com",
      "url": "https://adc.bmj.com/content/104/Suppl_2/A186.3",
      "authors": "adc.bmj.com",
      "host": "adc.bmj.com",
      "snippet": "by C Petrides · 2019 — Aim NICE has issued guidelines on anaphylaxis management in 2011. assessment, management and referral process of children treated for anaphylaxis. Good",
      "score": 0.6461259
    },
    {
      "number": 10,
      "title": "Anaphylaxis - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-gb/501",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "open menu\n\n# Anaphylaxis\n\nEpidemiology\n\nAetiology\n\nCase history\n\nRecommendations\n\nHistory and exam\n\nInvestigations\n\nDifferentials\n\nCriteria\n\nRecommendations\n\nTreatment algorithm\n\nEmerging\n\nPrevention\n\nPatient discussions\n\nMonitoring\n\nComplications\n\nPrognosis\n\nGuidelines\n\nImages and videos\n\nReference",
      "score": 0.48177138
    },
    {
      "number": 11,
      "title": "Anaphylaxis: a guide to management Online course",
      "detail": "new-learning.bmj.com",
      "url": "https://new-learning.bmj.com/course/5001088",
      "authors": "new-learning.bmj.com",
      "host": "new-learning.bmj.com",
      "snippet": "This course will help you to recognise and treat anaphylaxis in hospital, as well as educate patients on when and how to use adrenaline",
      "score": 0.4075462
    },
    {
      "number": 12,
      "title": "Anaphylaxis - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/501",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization anaphylaxis guidance 2020. World Allergy Organ J. 2020 Oct 30;13(10):100472.Full text30375-6/fulltext)Abstract\n\nGolden DBK, Wang J, Waserman S, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024",
      "score": 0.39789218
    },
    {
      "number": 13,
      "title": "Integrated phase I pharmacokinetics and ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1081120625000092",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by CN Kraus · 2025 · Cited by 10 — 12 mg or 0.3 mg EpiPen, 0.3 mg generic EpiPen, Epinephrine is the first-line treatment for anaphylaxis and is approved by the US Food and Drug Administration (",
      "score": 0.4362623
    },
    {
      "number": 14,
      "title": "Review Innovations in the treatment of anaphylaxis",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1081120623004040",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by JA Lieberman · 2023 · Cited by 40 — Current guidelines recommend ・ standard approved dose of 0.01 mg/kg of 1:1000 ・ single maximum dose of 0.5 mg in adults and 0.3 mg in children. Drug",
      "score": 0.4154922
    },
    {
      "number": 15,
      "title": "Generic substitution of epinephrine autoinjectors",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2772829323000954",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by SE Ray · 2024 · Cited by 1 — first-line treatment for anaphylaxis and suspected anaphylaxis is epinephrine 1 mg/mL solution immediately administered intramuscularly into the mid outer",
      "score": 0.2425737
    },
    {
      "number": 16,
      "title": "Pediatric drug-induced anaphylaxis reports in the FDA ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2213219824005737",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by A Brameli · 2024 · Cited by 10 — Previous research indicated that antibiotics and nonsteroidal anti-inflammatory drugs are key drug categories associated with anaphylaxis in children.",
      "score": 0.2048667
    },
    {
      "number": 17,
      "title": "NATIONAL INSTITUTE FOR HEALTH AND CLINICAL ...",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng258/evidence/anaphylaxis-full-guideline-appendix-c-and-d-pdf-184946942",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "7-8. EXC - commentary on Sampson et al (1992) Ameratunga R, Webster M, Patel H (2008) Unstable angina following anaphylaxis. Postgraduate Medical Journal 84: 659-61. EXC - not biphasic anaphlaxis Anaphylaxis: NICE clinical guideline appendix D Page 79 of 82 Banov CH (1991) Current review of anaphyla",
      "score": 0.7413937
    },
    {
      "number": 18,
      "title": "A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020)",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8996305",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": ". Muraro, Worm, Alviani, Cardona, DunnGalvin, Garvey, _et al._ (2022). EAACI Guidelines: Anaphylaxis (2021 Update). _Allergy_ 77 (2), 357–377. doi: 10.1111/all.15032  [DOI] [PubMed] [Google Scholar]\n   . National Guideline Clearinghouse [Internet] (2019). The Agency for Healthcare Research and Quali",
      "score": 0.72254705
    },
    {
      "number": 19,
      "title": "Overview | Anaphylaxis: assessment and referral after emergency treatment | Guidance | NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng258",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "Next review:This guideline will be reviewed if there is new evidence that is likely to change the recommendations.\n\n### Recommendations\n\nThis guideline includes recommendations on:\n\n### Who is it for?\n\n### Guideline development process\n\nHow we develop NICE guidelines\n\nThis guideline was previously c",
      "score": 0.6628188
    },
    {
      "number": 20,
      "title": "Management of Refractory Anaphylaxis: An Overview of Current Guidelines",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11439156",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Allergists, emergency physicians, intensivists, paediatricians and anaesthetists need to be aware of RA management, even if this is a rare event.\n\nWhereas a previous article focused on the need for a consensus on RA definition, in this narrative (nonsystematic) review on published guidelines regardi",
      "score": 0.64639384
    },
    {
      "number": 21,
      "title": "Evaluating the management of anaphylaxis in US emergency departments: Guidelines vs. practice",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4129832",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "At discharge, most patients were advised to follow-up with a physician (Figure 5). Of 198 respondents, 171 (86.4%) recommended that the patient see the primary care physician (PCP). Referrals for follow-up with an allergist, per guideline recommendations, were not as common – 83 respondents (41.9%) ",
      "score": 0.6227582
    },
    {
      "number": 22,
      "title": "Recent update on the management of anaphylaxis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8517462",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Clinical manifestations at the time of presentation are helpful in the diagnosis of anaphylaxis . Diagnostic criteria based on the guideline suggested by WAO in 2020 are 1) sudden onset of an illness (minutes to several hours) with simultaneous involvement of the skin, mucosal tissue, or both (gener",
      "score": 0.6063825
    },
    {
      "number": 23,
      "title": "Anaphylaxis - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK551995",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Cover of Anaphylaxis\n\n# Anaphylaxis\n\nA summary of selected new evidence relevant to NICE clinical guideline 134 ‘Anaphylaxis: assessment to confirm an anaphylactic episode and the decision to refer after emergency treatment for a suspected anaphylactic episode’ (2011)\n\nEvidence Update, No. 36\n\n## In",
      "score": 0.568632
    },
    {
      "number": 24,
      "title": "Anaphylaxis - StatPearls - NCBI Bookshelf - NIH",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK482124",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "## Evaluation\n\nDiagnosing anaphylaxis is clinical; thus, laboratory studies or other diagnostics are unnecessary. Most anaphylactic deaths occur within the first hour after antigen exposure. Rapid recognition and action are imperative.(#article-17514.r2)(#article-17514.r12)(#article-17514.r13) Consi",
      "score": 0.42520002
    }
  ],
  "publishedAt": "2026-08-20T23:42:18.428103Z",
  "updatedAt": "2026-08-20T23:42:18.428103Z",
  "readingMinutes": 5,
  "slug": "anaphylaxis"
}